[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wrinkle-appearance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wrinkle-appearance":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100651494","comparing-facial-aging-between-identical-twins-with-3d-imaging-100651494",false,"NCT07760532","Comparing Facial Aging Between Identical Twins With 3D Imaging","A Prospective Observational Study of Facial Aging in Identical Twins Using Three-Dimensional Imaging","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Members of a monozygotic (identical) twin pair, with both twins present and willing to participate\n* Able to provide written informed consent in English\n\nExclusion Criteria:\n\n* Age under 18 years\n* Inability or unwillingness to provide informed consent\n* Facial conditions or recent facial surgery that, in the investigator's judgment, would prevent standardized imaging\n* Pregnancy, by self-report\n\nNote: Zygosity is established by participant self-report, supported where available by prior DNA testing or physician confirmation. No genetic testing is performed and no biological specimens are collected. Pairs who self-report as dizygotic or are uncertain of their zygosity are recorded as such and analyzed separately from the confirmed monozygotic cohort.",true,"ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","Identical twins share the same genes, which makes them a powerful way to study how lifestyle and environment - rather than genetics - affect how faces age. This study builds on a landmark 2009 twin study by using modern three-dimensional (3D) facial imaging, which measures facial shape and volume precisely instead of relying on regular photographs. The study will also look at whether use of GLP-1 weight-loss medications (such as semaglutide or tirzepatide), sometimes associated with facial changes informally called \"Ozempic face,\" is related to measurable differences in facial aging.\n\nThe study will enroll adult identical twin pairs attending the Twins Days Festival in Twinsburg, Ohio, in August 2026. Participation takes about 30 minutes and happens in a single visit at the festival study booth. Each twin will complete a questionnaire about lifestyle, environment, and medical history (such as sun exposure, smoking, sleep, and medication use) and have a 3D image of their face taken with a non-contact camera system. There is no treatment, no medication, no blood draw or biological sample, and no follow-up visit. Researchers will then compare facial measurements within each twin pair to learn which lifestyle and environmental factors are linked to visible facial aging.",[25,26,27],"Facial Skin Aging","Facial Volume Loss","Wrinkle Appearance",[29,30,31,32,33,34,35,36],"identical twin study facial aging","identical twins with ozempic face","twins three-dimensional imaging","environmental factors that contribute to aging identical twins","Dr. Diana Ponsky Facial Aging Study","Dr. Diana Ponsky identical twin study","Dr. Diana Ponsky 3d study","Dr Diana Ponsky twins facial aging","NOT_YET_RECRUITING","2026-08-07",{"date":40,"type":41},"2026-08-12","ACTUAL",{"date":43,"type":21},"2026-08-08",{"date":45,"type":21},"2026-09",{"name":47,"class":48},"Ponsky Facial Aesthetics And Plastic Surgery, Llc","INDUSTRY",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":16,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":80,"locationsCount":4},"100627263","a-study-to-evaluate-the-efficacy-of-collagen-16-serum-alone-against-and-as-an-adjunct-to-radiesse-biostimulation-procedure-in-female-trial-participants-with-aged-skin-100627263","NCT07446361","A Study to Evaluate the Efficacy of Collagen 16 Serum Alone, Against and as an Adjunct to Radiesse® Biostimulation Procedure in Female Trial Participants With Aged Skin","A Randomized Clinical Study to Evaluate the Efficacy of Collagen 16 Serum Alone, Against and as an Adjunct to Radiesse® Biostimulation Procedure in Female Trial Participants With Aged Skin","Inclusion Criteria:\n\n* Female trial participants aged from 30 to 70 years.\n* Trial participants who are regular users of anti-aging cosmetic products.\n* Trial participants presenting with:\n* Wrinkle visibility score ≥3 and ≤6 on a 10-point visual scale.\n* Fine lines visibility score ≥3 and ≤6 on a 10-point visual scale.\n* Crow's feet wrinkle score ≥2 and ≤4 on the L'Oréal Atlas (volume 1 caucasian type).\n* Skin radiance score ≥3 and ≤6 on a 10-point visual scale.\n* Plumpness score ≥3 and ≤6 on a 10-point visual scale\n\nExclusion Criteria:\n\n* Trial participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.\n* Trial participants who are currently participating in another facial clinical study or who have participated in such a study within 1 month that may interfere with the study outcomes.\n* Trial participants presenting with current flaring or severe inflammatory acne or any active dermatological condition that, in the investigator's opinion, could interfere with study assessments.\n* Trial participants who have undergone ablative laser treatments, microneedling, chemical peels, dermabrasion, non-ablative laser, intense pulsed light (IPL), or injectable procedures within the last 12 months from the day of screening.\n* Trial participants who have undergone biostimulation procedures in the past 6 to 9 months from the day of screening\n* Trial participants with a known allergy to any component of the investigational product(s), comparator product(s), or additional products used in the study.\n* Trial participants presenting with any medical or dermatological condition that, in the investigator's opinion, may compromise trial participant safety or interfere with study conduct or evaluation.\n* Trial participants who are unable or unwilling to comply with the study requirements and instructions.\n* Trial participants who are unable to provide written informed consent.\n* Trial participant with clinically significant history of alcoholism or drug abuse;\n* Trial participant who are employees of MSCR or Sponsor","FEMALE","30 Years","70 Years",{"count":61,"type":21},180,"INTERVENTIONAL",[64],"NA","This study aims at assessing the efficacy of improving skin aging signs of a serum containing collagen 16 combined with a biostimulation device in healthy female subjects aged between 30 and 70 years over a period of 13 weeks.",[27,67],"Skin Quality",[69,70,71,72,73],"anti-aging","cosmetics","collagen 16","biostimulation","placebo serum","2026-03-02",{"date":76,"type":41},"2026-03-03",{"date":78,"type":21},"2026-03-01",{"date":45,"type":21},{"name":81,"class":48},"Vichy Laboratoires",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":62,"phases":92,"briefSummary":95,"conditions":96,"keywords":104,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100582895","phase-1-autologous-adipose-cells-therapy-100582895","NCT06869252","Autologous Adipose Cells Therapy","Inclusion Criteria:\n\n1. Outpatients who express interest in skin rejuvenation, and\u002For who are experiencing skin conditions, such as winkles, fine lines, loss of skin elasticity, skin pigmentation, scarring.\n2. Outpatients who are experiencing hair loss or hair thinning\n3. Provision of signed and dated informed consent form\n4. Clearly stated willingness to comply with all the procedures of the study and availability of the study\n5. Female and Male aged between 21 to 80 years old 6 Medical clearance by family doctor\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Known allergic reaction to components of cell culture media\n3. Chronic disease , e.g. cardiovascular disease, diabetes, chronic kidney disease, seizures\n4. Chronic infections, e.g. skin fungi infection, psoriasis\n5. Chronic wound healing\n6. Currently taking hormone therapy\n7. History of cancers and active cancers\n8. Viral infection, e.g. HIV, hepatitis B, influenza, coronaviruses.","21 Years","80 Years",{"count":91,"type":21},40,[93,94],"PHASE1","PHASE2","Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell Therapy for skin rejuvenation and hair improvement in human application.",[97,27,98,99,100,101,102,103],"Hair Loss\u002FBaldness","Volume","Fine Lines","Skin Elasticity","Hair Thinning","Skin Pigmentation","Skin Texture",[105,106],"Adipose Cells","Adipocytes","RECRUITING","2025-05-30",{"date":110,"type":41},"2025-05-31",{"date":112,"type":21},"2025-08-01",{"date":114,"type":21},"2026-02-01",{"name":116,"class":48},"CERM INC.",2]